Day One Biopharmaceuticals (NASDAQ:DAWN) Posts Earnings Results, Misses Estimates By $0.34 EPS

Day One Biopharmaceuticals (NASDAQ:DAWN) posted its quarterly earnings data on Tuesday. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.34), Zacks reports.

Day One Biopharmaceuticals Stock Performance

Day One Biopharmaceuticals stock traded down $0.36 during midday trading on Tuesday, reaching $11.82. The stock had a trading volume of 1,385,338 shares, compared to its average volume of 985,204. The stock has a market capitalization of $1.19 billion, a PE ratio of -11.48 and a beta of -1.46. The stock’s 50-day simple moving average is $12.36 and its 200 day simple moving average is $13.47. Day One Biopharmaceuticals has a twelve month low of $11.13 and a twelve month high of $18.07.

Insiders Place Their Bets

In related news, CFO Charles N. York II sold 4,370 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $52,265.20. Following the completion of the sale, the chief financial officer now directly owns 252,638 shares of the company’s stock, valued at approximately $3,021,550.48. This represents a 1.70 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel Adam Dubow sold 4,646 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total value of $55,566.16. Following the completion of the transaction, the general counsel now directly owns 39,602 shares in the company, valued at $473,639.92. This trade represents a 10.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 51,064 shares of company stock worth $651,225 over the last three months. 8.40% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research firms have issued reports on DAWN. Bank of America reduced their target price on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a research report on Thursday, October 31st. TD Cowen raised Day One Biopharmaceuticals to a “strong-buy” rating in a research note on Monday, November 4th. The Goldman Sachs Group lowered their price objective on Day One Biopharmaceuticals from $48.00 to $43.00 and set a “buy” rating for the company in a research report on Monday, February 10th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Monday, January 13th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Day One Biopharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $35.71.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.